Comorbidity and geriatric assessment for older patients with hematologic malignancies: A review of the evidence

Journal of Geriatric Oncology

Volumn 3, Issue 1, 2012, Pages 49-57

  Extermann, M ^a   Wedding, U ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

ADL; CGA; Charlson; CIRS G; CLL; Comorbidity; Frailty; Geriatric syndromes; Hematopoietic cell; IADL; Leukemia; Lymphoma; MDS; Myeloma; Predictive scores

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DRUG FATALITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FRAIL ELDERLY; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GERIATRIC CARE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INSTRUMENT VALIDATION; INTENSIVE CARE UNIT; LARGE CELL LYMPHOMA; LEUKOPENIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYPHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SOCIAL CLASS;

EID: 84856360383     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2011.11.004     Document Type: Review

References (57)

1. Extermann M., Aapro M., Bernabei R., Cohen H.J., Droz J.P., Lichtman S., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005, 55(3):241-252.
2. NCCN NCCN Guidelines™ [cited; Available from:. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
3. Walter L.C., Covinsky K.E. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001, 285(21):2750-2756.
4. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5(3):224-237.
5. Extermann M. Basic Assessment of the Older Cancer Patient. Curr Treat Options Oncol Sep 2011, 12(3):276-285.
6. McCorkle R., Strumpf N.E., Nuamah I.F., Adler D.C., Cooley M.E., Jepson C., et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 2000, 48(12):1707-1713.
7. Caillet P., Canoui-Poitrine F., Vouriot J., Berle M., Reinald N., Krypciak S., et al. Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study. J Clin Oncol Sep 20 2011, 29(27):3636-3642.
8. Extermann M., Meyer J., McGinnis M., Crocker T.T., Corcoran M.B., Yoder J., et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 2004, 49(1):69-75.
9. Audisio R.A., Pope D., Ramesh H.S., Gennari R., van Leeuwen B.L., West C., et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008, 65(2):156-163.
10. Soejono C. The role of comprehensive geriatric assessement (CGA) in the management of stage 3 hepatocellular carcinoma in the elderly. Crit Rev Oncol Hematol 2006, 60(S1):S20.
11. Freyer G., Geay J.F., Touzet S., Provencal J., Weber B., Jacquin J.P., et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005, 16(11):1795-1800.
12. Overcash J.A., Beckstead J. Predicting falls in older patients using components of a comprehensive geriatric assessment. Clin J Oncol Nurs 2008, 12(6):941-949.
13. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
14. Miller M.D., Paradis C.F., Houck P.R., Mazumdar S., Stack J.A., Rifai A.H., et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992, 41(3):237-248.
15. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000, 36(4):453-471.
16. Wedding U., Rohrig B., Klippstein A., Pientka L., Hoffken K. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 2007, 133(12):945-950.
17. Zaheer W., Hashmi A., Lichtman S.M., Kolitz J., Cirrone K., Spinek K., et al. Effect of comorbidity and age on survival in 73 patients with de novo acute leukemia. Proc Am Soc Clin Oncol 1995, 498.
18. Etienne A., Esterni B., Charbonnier A., Mozziconacci M.J., Arnoulet C., Coso D., et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007, 109(7):1376-1383.
19. Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106(8):2912-2919.
20. Harb A.J., Tan W., Wilding G.E., Ford L., Sait S.N., Block A.W., et al. Treating octogenarian and nonagenarian acute myeloid leukemia patients-predictive prognostic models. Cancer 2009, 115(11):2472-2481.
21. Sperr W.R., Wimazal F., Kundi M., Baumgartner C., Nosslinger T., Makrai A., et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010, 21(1):114-119.
22. Winkelmann N., Petersen I., Kiehntopf M., Fricke H.J., Hochhaus A., Wedding U. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011, 137(4):733-738.
23. Tucci A., Ferrari S., Bottelli C., Borlenghi E., Drera M., Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009, 115(19):4547-4553.
24. Thurmes P., Call T., Slager S., Zent C., Jenkins G., Schwager S., et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008, 49(1):49-56.
25. Moran J.L., Solomon P.J., Williams P.J. Assessment of outcome over a 10-year period of patients admitted to a multidisciplinary adult intensive care unit with haematological and solid tumours. Anaesth Intensive Care 2005, 33(1):26-35.
26. Chen-Hardee S., Chrischilles E.A., Voelker M.D., Brooks J.M., Scott S., Link B.K., et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 2006, 17(5):647-654.
27. Lyman G.H., Delgado D.J. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003, 98(11):2402-2409.
28. Gruschkus S.K., Lairson D., Dunn J.K., Risser J., Du X.L. Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy. J Am Geriatr Soc 2010, 58(10):1885-1895.
29. Brunello A., Kapoor R., Extermann M. Hyperglycemia During Chemotherapy for Hematologic and Solid Tumors Is Correlated With Increased Toxicity. Am J Clin Oncol June 2011, 34(3):292-296.
30. Shanafelt T.D., Bowen D., Venkat C., Slager S.L., Zent C.S., Kay N.E., et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 2007, 139(2):255-264.
31. Wedding U., Rohrig B., Klippstein A., Brix C., Pientka L., Hoffken K. Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients. Support Care Cancer 2007, 15(9):1097-1104.
32. van Spronsen D.J., Janssen-Heijnen M.L., Lemmens V.E., Peters W.G., Coebergh J.W. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 2005, 41(7):1051-1057.
33. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174.
34. Wildes T.M., Augustin K.M., Sempek D., Zhang Q.J., Vij R., Dipersio J.F., et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14(7):840-846.
35. Labonte L., Iqbal T., Zaidi M.A., McDiarmid S.A., Huebsch L.B., Tay J., et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008, 14(9):1039-1044.
36. Artz A.S., Pollyea D.A., Kocherginsky M., Stock W., Rich E., Odenike O., et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006, 12(9):954-964.
37. Pollack S.M., Steinberg S.M., Odom J., Dean R.M., Fowler D.H., Bishop M.R. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15(2):223-230.
38. Farina L., Bruno B., Patriarca F., Spina F., Sorasio R., Morelli M., et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009, 23(6):1131-1138.
39. Juliusson G., Antunovic P., Derolf A., Lehmann S., Mollgard L., Stockelberg D., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113(18):4179-4187.
40. Lowenberg B., Zittoun R., Kerkhofs H., Jehn U., Abels J., Debusscher L., et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989, 7(9):1268-1274.
41. van Heeckeren W., Fu P., Barr P.M., Arfons L.M., Kirschbaum M.H., Lazarus H.M., et al. Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia. J Geriatr Oncol 2011, 2(3):215-221.
42. Anonymous A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329(14):987-994.
43. Wedding U., Rohrig B., Klippstein A., Fricke H.J., Sayer H.G., Hoffken K. Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 2006, 132(10):665-671.
44. Lobato-Mendizabal E., Lopez-Martinez B., Ruiz-Arguelles G.J. A critical review of the prognostic value of the nutritional status at diagnosis in the outcome of therapy of children with acute lymphoblastic leukemia. Rev Invest Clin 2003, 55(1):31-35.
45. Robb C., Boulware D., Overcash J., Extermann M. Patterns of care and survival in cancer patients with cognitive impairment. Crit Rev Oncol Hematol 2010, 74(3):218-224.
46. Soubeyran P., Khaled H., MacKenzie M., Debois M., Fortpied C., de Bock R., et al. Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly. A phase II EORTC trial with a progressive and cuatious treatment emphasizing geriatric assessment. J Geriatr Oncol 2011, 2(1):36-44.
47. Monfardini S., Aversa S.M., Zoli V., Salvagno L., Bianco A., Bordonaro R., et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann Oncol 2005, 16(8):1352-1358.
48. Balducci L., Extermann M., Carreca I. Management of breast cancer in the older woman. Cancer Control 2001, 8(5):431-441.
49. Tirelli U., Fratino L., Balzarotti M., Uziel L., Giacalone A., Ferreri A., et al. Comprehensive geriatric assessment-adapted chemotherapy in elderly patients (>70 years) with diffuse large cell B cell non-Hodgkin's lymphoma (DLCBL): final results and long term follow-up. Blood 2009, 114(22):1050.
50. Hurria A., Togawa K., Mohile S.G., Owusu C., Klepin H.D., Gross C.P., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. Journal of clinical oncology. Am Soc Clin Oncol 2011, 29(25):3457-3465.
51. Extermann M., Boler I., Reich R.R., Lyman G.H., Brown R.H., Defelice J., et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2011, (Electronic publication ahead of print Nov 9).
52. Extermann M., Bonetti M., Sledge G.W., O'Dwyer P.J., Bonomi P., Benson A.B. MAX2-a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer 2004, 40(8):1193-1198.
53. Intragumtornchai T., Sutheesophon J., Sutcharitchan P., Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000, 37(3-4):351-360.
54. Blay J.Y., Chauvin F., Le Cesne A., Anglaret B., Bouhour D., Lasset C., et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996, 14(2):636-643.
55. Borg C., Ray-Coquard I., Philip I., Clapisson G., Bendriss-Vermare N., Menetrier-Caux C., et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004, 101(11):2675-2680.
56. Ray-Coquard I., Borg C., Bachelot T., Sebban C., Philip I., Clapisson G., et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003, 88(2):181-186.
57. Janssen-Heijnen M.L., Extermann M., Boler I.E. Can first cycle CBCs predict older patients at very low risk of neutropenia during further chemotherapy?. Crit Rev Oncol Hematol 2011, 79(1):43-50.